The FDA has approved Forteo (teriparatide [rDNA origin] injection, from Lilly) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture. This approval was based on data from a clinical study which showed that in patients with glucocorticoid-induced osteoporosis, Forteo increased bone mineral density (BMD) from baseline to 18 months of treatment by 7.2% at the lumbar spine, 3.6% at the total hip, and 3.7% at the femoral neck.

Forteo is already indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture and to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

For more information call (800) 545-5979 or visit www.forteo.com.